modelOtherPlasmaProteinFracti
Extends from Pharmacolibrary.Drugs.ATC.B.B05AA02.
Information
| name: | OtherPlasmaProteinFractions | |
| ATC code: | B05AA02 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 0.08 | liter/hour |
| other parameters in model implementation | ||
Other plasma protein fractions are purified preparations containing a variety of plasma proteins excluding immunoglobulins. They are typically used as plasma expanders in the treatment or prevention of shock due to blood loss, burns, or hypoalbuminemia, especially when plasma or albumin is not available. Their use today is limited due to improved alternatives such as albumin solutions, crystalloids, and colloids. Not currently a first-line therapy and rarely used in modern clinical practice.
Pharmacokinetics
Estimated typical pharmacokinetic parameters for intravenous administration in adult humans, as specific published PK studies for this ATC-defined group are lacking.
References
Tan, AR, et al., & Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology 22(1) 85–97. DOI:10.1016/S1470-2045(20)30536-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33357420
Sandri, AM, et al., & Zavascki, AP (2013). Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 57(4) 524–531. DOI:10.1093/cid/cit334 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23697744
Jansen, AME, et al., & Brüggemann, RJM (2022). Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 28(7) 1003–1009. DOI:10.1016/j.cmi.2022.01.029 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35150880
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)